Hepatocellular Carcinoma Research

HCC research explores IO-based combinations, locoregional-systemic integration, and treatment sequencing by liver function and tumor burden.

Our Hepatocellular Carcinoma Analysis

• July 30, 2026JAMA OncologyTORCH (NCT02435953)

  TACE Plus Thermal Ablation Nearly Halves Progression Risk in Intermediate-Stage Liver Cancer

  Phase 3 TORCH trial (241 patients, two tertiary centers in China, enrolled 2015-2024) randomized adults with unresectable, liver-confined, intermediate-stage (BCLC stage B) hepatocellular carcinoma 1:1 to transarterial chemoembolization (TACE) plus sequential radiofrequency ablation versus TACE alone.

• July 17, 2026Clinical Cancer ResearchPooled Mixture-Cure-Model Analysis of HIMALAYA (NCT03298451), CheckMate 9DW (NCT04039607), RATIONALE-301 (NCT03412773)

  Immunotherapy Achieves Durable Survival, Modest Cure Fractions in Advanced Liver Cancer

  A pooled, secondary mixture-cure-model analysis of three mature Phase III trials (HIMALAYA, CheckMate 9DW, RATIONALE-301) plus a large real-world cohort estimates how many patients with advanced hepatocellular carcinoma (HCC) achieve durable, cure-like outcomes on first-line immune checkpoint inhibitor (ICI) regimens.